There are tens of thousands of unknown molecules circulating in human blood – thousands of which could represent robust biomarkers. Sapient uses our next-generation rapid liquid chromatography-mass spectrometry (rLC-MS) systems to provide nontargeted metabolomics services, rapidly measuring >15,000 small molecule biomarkers per biosample to identify key molecules of interest – including yet-unmapped chemistries. We then leverage a comprehensive follow-on technology pipeline to enable targeted profiling of the small molecule chemistries identified.
Download the infographic to see how Sapient leverages its high-powered methods to help biopharma sponsors identify and translate novel small molecule biomarkers at speed, scale, and with high specificity,
Chemistries & Methods: How We Achieve Breadth and Depth in Chemical Discovery
There are tens of thousands of unknown molecules circulating in human blood – thousands of which could represent robust biomarkers. Sapient uses our next-generation rapid liquid chromatography-mass spectrometry (rLC-MS) systems to provide nontargeted metabolomics services, rapidly measuring >15,000 small molecule biomarkers per biosample to identify key molecules of interest –… Read More
What is Discovery at Scale? Multiplying the Rate of Nontargeted Biomarker Profiling
A drug candidate with an associated biomarker is 2−10x more likely to obtain FDA approval. Why? Because biomarkers help to stratify patient populations by elucidating the involvement of specific genes, proteins, and molecular alterations that give rise to their disease state. Therapies can then be aligned with patients most likely… Read More
